Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Latest Insights for Elanco Animal Health (ELAN) Shareholders

Shares of Health Care sector company Elanco Animal Health moved 2.3% today, and are now trading at a price of $14.85. The Mid-Cap stock's daily volume was 2,375,641 compared to its average volume of 5,867,455. The S&P 500 index returned a 1.0% performance.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company is based in Greenfield and has 9,000 full time employees. Its market capitalization is $7,372,710,400.

11 analysts are following Elanco Animal Health and have set target prices ranging from $10.0 to $18.0 per share. On average, they have given the company a rating of buy. At today's prices, ELAN is trading -0.13% away from its average analyst target price of $14.86 per share.

Over the last year, ELAN's share price has increased by 12.4%, which represents a difference of 1.8% when compared to the S&P 500. The stock's 52 week high is $15.78 per share whereas its 52 week low is $8.02. With average free cash flows of $175.67 Million that have been growing at an average rate of 36.2% over the last 5 years, Elanco Animal Health is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2024 541,000 147,000 394,000 200.76
2023 271,000 140,000 131,000 -53.38
2022 452,000 171,000 281,000 -13.27
2021 483,000 159,000 324,000 302.5
2020 -41,000 119,000 -160,000 -290.48
2019 224,000 140,000 84,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS